Specialty vaccine developer Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced successful Phase 2 clinical trial results on November 9, 2026, for its investigational tetravalent bioconjugate vaccine candidate Shigella4V2 (S4V2). Reported from corporate headquarters in Lyon, France, the clinical dataset incorporates findings from a pediatric safety and immunogenicity trial in infants and an adult Controlled Human Infection Model (CHIM) study. The candidate demonstrated an encouraging safety profile alongside statistically significant immunogenicity and protective efficacy signals.
Shigellosis burden and S4V2 antibody responses in infants
Shigellosis is a severe enteric infection caused by the Gram-negative bacterium Shigella, recognized by the World Health Organization as a leading global cause of bacterial diarrhea and mortality. The disease claims over 200,000 lives annually, with young children under five years old in low- and middle-income countries bearing disproportionate mortality. The crisis is compounded by the rapid emergence of antimicrobial resistance, with multi-drug resistant strains exhibiting resistance to ciprofloxacin and third-generation cephalosporins exceeding 70% in endemic regions.
Valneva's S4V2 is the world's most clinically advanced tetravalent bioconjugate vaccine targeting the four predominant epidemiological strains: Shigella flexneri serotypes 2a, 3a, 6, and Shigella sonnei.
In the infant immunogenicity trial, the vaccine induced robust functional bactericidal antibody responses across all four targeted serotypes, with seroconversion rates exceeding 85% following the primary pediatric series.
S4V2 cuts dysentery 68.5% in human challenge trial
In the controlled human challenge trial, healthy adult volunteers who received S4V2 demonstrated a 68.5% reduction in symptomatic bacterial dysentery compared to unvaccinated controls following oral challenge with wild-type virulent bacteria. Both clinical cohorts confirmed an excellent systemic safety profile without vaccine-related serious adverse events.
During an investor conference call, Dr. Hanneke Schuitemaker, Chief Scientific Officer of Valneva, underlined the global health imperative guiding the program. Dr. Schuitemaker stated: "These studies provide important clinical data on the safety, immunogenicity and preliminary efficacy of our tetravalent candidate to prevent pediatric bacterial diarrhea."
Valneva is preparing for end-of-Phase 2 consultations with international regulatory authorities and the World Health Organization to finalize pivotal Phase 3 study designs. Global registrational Phase 3 trials are scheduled to initiate across endemic sites in sub-Saharan Africa and South Asia during the second half of 2027.
Experts back S4V2 against resistant Shigella strains
Infectious disease researchers and pediatric public health officials underscored that shigellosis remains a devastating neglected bacterial disease demanding effective prophylactic vaccination solutions. The alarming global spread of antimicrobial resistance across Shigella isolates threatens to render conventional empirical antibiotic therapies ineffective across developing regions. Valneva's tetravalent bioconjugate candidate addresses this critical epidemiological need by providing broad antigenic coverage across the four predominant pathogenic serotypes responsible for global morbidity. The favorable safety profile and robust functional antibody generation demonstrated across pediatric cohorts establish a strong clinical foundation for upcoming registrational trials in endemic jurisdictions. International vaccine alliances and philanthropic health organizations welcomed the Phase 2 dataset, noting that an effective pediatric shigella vaccine could save tens of thousands of young lives annually.
Global health economists and vaccine development specialists underscored that deploying effective bacterial vaccines provides a durable defense against antimicrobial resistance. Preventing severe pediatric diarrheal disease reduces infant mortality and alleviates heavy clinical burdens on healthcare infrastructures across developing nations. Valneva's Phase 2 clinical success establishes a promising trajectory toward commercializing the first approved broad-spectrum vaccine candidate against shigellosis.
Pediatric infectious disease specialists emphasized that developing safe, multi-serotype preventative vaccines is essential for reducing global childhood dysentery mortality. Prophylactic immunization provides an invaluable clinical tool to curb reliance on broad-spectrum antibiotics and slow the emergence of dangerous multidrug-resistant bacterial strains. Valneva's positive Phase 2 findings provide a robust empirical foundation as international public health consortia prepare for pivotal Phase 3 pediatric trials across endemic regions.
